FY2026 EPS Estimates for Gilead Sciences Raised by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Erste Group Bank increased their FY2026 earnings per share (EPS) estimates for Gilead Sciences in a report released on Friday, September 18th. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will post earnings per share of ($0.44) for the year, up from their prior estimate of ($0.45). The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.48) per share.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm’s revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.01 earnings per share.

A number of other brokerages also recently weighed in on GILD. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Barclays lowered their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday. Truist Financial cut their target price on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Finally, Royal Bank Of Canada increased their target price on Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $158.78.

Gilead Sciences Stock Performance

Shares of GILD opened at $150.56 on Tuesday. Gilead Sciences has a 12-month low of $108.46 and a 12-month high of $157.29. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company has a market cap of $186.69 billion, a PE ratio of -56.39 and a beta of 0.33. The stock has a 50-day moving average price of $140.37 and a 200-day moving average price of $136.24.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Persistent Asset Partners Ltd purchased a new stake in Gilead Sciences during the 2nd quarter valued at about $25,000. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences in the 4th quarter worth approximately $25,000. Kimelman & Baird LLC bought a new stake in Gilead Sciences in the second quarter valued at approximately $25,000. Wealth Preservation Advisors LLC boosted its stake in shares of Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 81 shares during the period. Finally, Wilkerson Advisory Group LLC boosted its stake in shares of Gilead Sciences by 54.2% during the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 78 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $145.29, for a total value of $435,870.00. Following the transaction, the chief financial officer owned 164,096 shares in the company, valued at $23,841,507.84. This trade represents a 1.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the sale, the director directly owned 12,894 shares of the company’s stock, valued at $1,916,306.28. This represents a 58.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 105,000 shares of company stock worth $14,616,390. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.